BioSpace News Archive

Twist Bioscience Corporation (NASDAQ: TWST), today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10 at 4:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time.

POINT Biopharma Global Inc., a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, announced the appointment of Matthew Vincent, Ph.D., J.D., as Senior Vice President, Business Development.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic, cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that it will present a corporate overview at the H.C. Wainwright BIOCONNECT Conference, held virtually January 10-13, 2022.

Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, today announced that Jim Burns, PhD, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 11:30 a.m. ET.

Hamburg, Germany, based Mindpeak and Spokane, WA, based Gestalt Diagnostics have achieved a major success on their way to improve patient care with Digital Pathology and Artificial Intelligence (AI)

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), today announced that the empty capsule material that makes up PharmaCyte’s CypCaps® pancreatic cancer product candidate is not toxic for the encapsulated cells inside the CypCaps.

ModivCare Inc. today announced that Dan Greenleaf, President and Chief Executive Officer, and Heath Sampson, Chief Financial Officer, are scheduled to present at the following upcoming investor conference.

Entera Bio Ltd . (NASDAQ: ENTX), today announced it has concluded its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on EB613.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (G.I.) diseases, today announced that the Company will participate in the H.C. Wainwright BIOCONNECT Conference occurring virtually on January 10 – 13, 2022.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the paper entitled “Dose Limiting, Adverse Event Associated Bradycardia with β-blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial” (William Abraham, et al) has been published in Heart Rhythm O2, a publication of the Hearth Rhythm Society.